Clinical implications of autoantibody screening in patients with autoimmune myositis

Ghirardello, Anna; Zampieri, Sandra; Tarricone, Elena; Iaccarino, Leonardo; Bendo, Raffaele; Briani, Chiara; Rondinone, R; Sarzi-Puttini, Piercarlo; Todesco, S; Doria, Andrea

doi:10.1080/08916930600622645

Cited by 93 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been emerging interest into the role of myositis-associated autoantibodies (MAA) and myositis-specific autoantibodies (MSA) in both clinical phenotype and prognostication [14][15][16]. The MAAs include antibodies directed to U1-RNP, Ro/SS-A and PMScl, whilst MSAs include antibodies to aminoacyl tRNA synthetases (anti-ARS), signal recognition particle (anti-SRP) and Mi-2 (anti-Mi-2).…”

Section: Introductionmentioning

confidence: 99%

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to determine the HLA and autoantibody associations of patients with histologically confirmed idiopathic inflammatory myositis (IIM). Serum and DNA were archived from South Australian patients with biopsy-proven dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM). HLA typing for Class I and II alleles was performed by serology and DNA-based technology, respectively, for 133 myositis patients and 166 Caucasian population-based controls. Myositis-specific and myositis-associated autoantibodies were detected by line immunoblot. All alleles of the 8.1AH were associated with myositis susceptibility. The B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups. Autoantibodies were present in 42/130 (32%) IIM patients and were more frequent in DM (11/17, 65%) than PM (23/70, 33%) or IBM (8/43, 19%), P = 0.002. Autoantibodies were associated with DRB1 03 (P = 0.0005) but also with DRB1 04 (P = 0.004). The frequency of autoantibodies in the three myositis subgroups mirrored the frequency of DR4. Polyarthralgia (±synovitis) was more common in DM/PM (30/76, 39%) than IBM (3/32, 9%), P = 0.004, and there was a strong ordinal association between the prevalence of autoantibodies and polyarthralgia ± synovitis (proportional OR = 5.5, 95% CI 2.3-13.7, P = 0.0004). The central MHC region confers the strongest susceptibility for IIM and also modulates disease phenotype. Our findings reveal a novel association of autoantibodies with DR4 and with arthralgia/synovitis in IIM and raise the possibility of a genetically (DR4) determined citrullination of myositis autoantigens expressed in muscle and synovium.

show abstract

Section: Introductionmentioning

confidence: 99%

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…69 Polymyositis is characterized by a CD8 þ T-cell response against muscle antigens presented by MHC Class I molecules. On the other hand, dermatomyositis is marked by a complement-mediated microangiopathy, typically mediated by type I IFN phenotype and autoantibodies with distinct specificities 70,71 ; however, the exact mechanism involved in complement activation remains unclear. 72 Current biological treatments in polymyositis/dermatomyositis include blockade of cells and cytokines, including B-cells by rituximab, 73 T cells by abatacept and cytokines by anti-IL-1, anti-IL-6 or anti-IFNa monoclonal antibodies.…”

Section: Polymyositis/dermatomyositismentioning

confidence: 99%

Galectin-3 in autoimmunity and autoimmune diseases

Oliveira

Gatto

Bassi

et al. 2015

Exp Biol Med (Maywood)

147

View full text Add to dashboard Cite

Galectin-3 (gal-3) is a b-galactoside-binding lectin, which regulates cell-cell and extracellular interactions during self/ non-self-antigen recognition and cellular activation, proliferation, differentiation, migration and apoptosis. It plays a significant role in cellular and tissue pathophysiology by organizing niches that drive inflammation and immune responses. Gal-3 has some therapeutic potential in several diseases, including chronic inflammatory disorders, cancer and autoimmune diseases. Gal-3 exerts a broad spectrum of functions which differs according to its intra-or extracellular localization. Recombinant gal-3 strategy has been used to identify potential mode of action of gal-3; however, exogenous gal-3 may not reproduce the functions of the endogenous gal-3. Notably, gal-3 induces monocyte-macrophage differentiation, interferes with dendritic cell fate decision, regulates apoptosis on T lymphocytes and inhibits B-lymphocyte differentiation into immunoglobulin secreting plasma cells. Considering the influence of these cell populations in the pathogenesis of several autoimmune diseases, gal-3 seems to play a role in development of autoimmunity. Gal-3 has been suggested as a potential therapeutic agent in patients affected with some autoimmune disorders. However, the precise role of gal-3 in driving the inflammatory process in autoimmune or immune-mediated disorders remains elusive. Here, we reviewed the involvement of gal-3 in cellular and tissue events during autoimmune and immune-mediated inflammatory diseases.

show abstract

“…14 Anti Mi-2 antibodies, anti Jo-1 (antihistidyl transfer RNA [t-RNA] synthetase), anti Signal Recognition Protein (anti SRP), anti PM-Scl and anti Ku antibodies can be present in myositis. 15 Anti Mi-2 antibodies have high specificity but low sensitivity for dermatomyositis. Anti Jo-1 antibody is more common in polymyositis.…”

Section: Discussionmentioning

confidence: 99%

Overlap Syndrome in a 13- Year- Old Girl: A Case Report

et al. 2014

View full text Add to dashboard Cite

The Overlap Syndrome is a rare condition which comprises two or more connective tissue disease in a same patient. Among them, some are associated with specific autoantibody profile and some are not. Here, we reported a case of overlap syndrome who presented with seizures and features of systemic lupus erythematosus, systemic sclerosis with the presence of strongly positive ANA, Anti snRNP, Anti Scl-70 antibody and weakly positive Anti Sm antibody.DOI: http://dx.doi.org/10.3329/jom.v14i2.19694 J Medicine 2013, 14(2): 218-221

show abstract

Clinical implications of autoantibody screening in patients with autoimmune myositis

Abstract: Searching for MSA and MAA in patients with autoimmmune myositis is recommended because of its diagnostic and clinical value. Anti-ARS non-Jo-1 antibodies seem to preferentially target patients with pulmonary fibrosis without overt myopathy.

Cited by 93 publications

References 32 publications

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis

Galectin-3 in autoimmunity and autoimmune diseases

Overlap Syndrome in a 13- Year- Old Girl: A Case Report

Contact Info

Product

Resources

About